Sannes Mark R, Kuskowski Michael A, Owens Krista, Gajewski Abby, Johnson James R
Mucosal and Vaccine Research Center and Medical Service, Veterans Affairs Medical Center, Minneapolis, Minnesota,USA.
J Infect Dis. 2004 Dec 15;190(12):2121-8. doi: 10.1086/425984. Epub 2004 Nov 15.
Escherichia coli is the most common cause of gram-negative bloodstream infections, causing an estimated 40,000 deaths from sepsis each year in the United States. The present study sought to determine specifically which virulence factors (VFs) and phylogenetic groups of E. coli are epidemiologically associated with bacteremia.
E. coli isolates from 63 veterans with bacteremia and rectal isolates from 71 matched uninfected control subjects were compared both for phylogenetic group and for the presence of VFs and O antigens.
Bacteremia isolates exhibited a significantly greater prevalence of most VFs studied. In multivariate logistic regression analysis, ompT (outer membrane protein T) was the strongest VF predictor of bacteremia (P<.001). Despite the concentration of most individual VFs within group B2, bacteremia and rectal isolates differed little by phylogenetic distribution, a finding explained by the greater prevalence of VFs among bacteremia isolates than rectal isolates within groups B2 and D.
Although phylogenetic group partially corresponds with virulence potential in E. coli bacteremia, VFs are more-powerful predictors of pathogenic potential. Bacteremia isolates exhibit an arsenal of VFs that distinguishes them from rectal isolates from uninfected hosts, which makes these differences attractive potential targets in vaccine or drug development.
大肠杆菌是革兰氏阴性血流感染最常见的病因,在美国每年估计有40,000人死于败血症。本研究旨在具体确定大肠杆菌的哪些毒力因子(VFs)和系统发育群与菌血症在流行病学上相关。
比较了63例菌血症退伍军人的大肠杆菌分离株和71例匹配的未感染对照受试者的直肠分离株的系统发育群以及VFs和O抗原的存在情况。
菌血症分离株显示出所研究的大多数VFs的患病率显著更高。在多变量逻辑回归分析中,ompT(外膜蛋白T)是菌血症最强的VF预测因子(P<0.001)。尽管大多数单个VFs集中在B2组内,但菌血症和直肠分离株在系统发育分布上差异不大,这一发现可通过B2组和D组内菌血症分离株中VFs的患病率高于直肠分离株来解释。
尽管系统发育群在一定程度上与大肠杆菌菌血症的毒力潜力相对应,但VFs是致病潜力更强的预测因子。菌血症分离株表现出一系列VFs,使其与未感染宿主的直肠分离株区分开来,这使得这些差异成为疫苗或药物开发中具有吸引力的潜在靶点。